INFO & CONTACTS:  +39 02 2390 1

A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors

Phase: Phase I-II clinical trials

Principal Investigator: Dott. Di Nicola Massimo

Main Facility: Unità Studi Clinici di Fase 1 (Early clinical Drug Development Team-ECDD)

Drug: BMS-986482, Nivolumab, Relatlimab, Bevacizumab

Pathologies: Advanced Solid Tumours, Melanoma, Pancreatic cancer, Lung cancer, Breast cancer, Intestinal cancer, Head and neck cancers, Stomach tumors, Urological cancers (kidney, bladder, urinary tract, others)

ClinicalTrials.gov: Read the details about clinical trials

This protocol is an open-label, multi-center, first-in-human (FIH) phase 1/2 study testing the safety and efficacy of BMS-986482 alone and in combination with nivolumab, with nivolumab and relatlimab, or in combination with bevacizumab in advanced solid tumors.

BMS-986482 is an orally administered, Ikaros-family zinc finger pan-degrader (IKZF-PD) with deep HELIOS+EOS and moderate IKAROS+AIOLOS degradation activity. It is designed to induce regulatory T (Treg) cell reprogramming and activation of effector T cells to boost antitumor immunity and improve outcomes in solid tumor indications.

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe